Last Updated: May 31, 2026

List of Excipients in Branded Drug UP AND UP NIGHTTIME SLEEP AID


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing UP AND UP NIGHTTIME SLEEP AID

Excipient Strategy and Commercial Opportunities for UP AND UP NIGHTTIME SLEEP AID

Last updated: March 3, 2026

What are the key excipient considerations for UP AND UP NIGHTTIME SLEEP AID?

The formulation employs excipients primarily to ensure stability, enhance bioavailability, and improve patient compliance. The typical excipients likely include binders, disintegrants, flow agents, and preservatives.

Common excipients in sleep aids:

  • Hypromellose: used in controlled-release formulations.
  • Magnesium stearate: lubricant to facilitate manufacturing.
  • Microcrystalline cellulose: filler and disintegrant.
  • Silica dioxide: flow agent.

Attention to excipient compatibility with active ingredients, especially insomnia drugs like diphenhydramine or doxylamine, reduces risks of instability or adverse effects.

How does excipient selection impact formulation performance?

Excipient choices influence drug release profiles, shelf life, and manufacturing process. For example, disintegrants control how quickly the tablet dissolves, affecting onset time of sleep aid. Use of certain binders may prolong release, resulting in longer-lasting effects. Incorporating moisture barriers can extend shelf life, especially in humid climates.

What are the commercial opportunities linked to excipient strategies?

1. Differentiation through advanced excipient platforms

Utilize novel excipients such as lipid-based carriers or polymer matrices to create formulations with enhanced bioavailability or reduced dosing frequency. These innovations can justify premium pricing.

2. Licensing and supply chain opportunities

Partner with excipient manufacturers to secure exclusive access to high-quality, FDA-compliant excipients. Large-volume contracts or proprietary excipient blends can generate steady revenue streams.

3. Patent enhancement and formulation exclusivity

Develop unique excipient combinations that can be patented, extending product exclusivity and market barriers. This generates a downstream competitive advantage.

4. Expansion into new delivery systems

Explore novel delivery formats such as orodispersible films or melt-in-your-mouth tablets incorporating innovative excipients. These formats appeal to specific demographics, such as elderly consumers or children.

5. Regulatory and quality control service offerings

Offer expertise or outsourced testing to demonstrate excipient compatibility and stability. This accelerates regulatory approval processes and reduces time-to-market.

What are recent patent trends associated with excipients in sleep aids?

Recent patents focus on excipient innovations for controlled-release mechanisms:

  • Use of lipids to modulate drug release over 8-12 hours (Patent US 10543215).
  • Novel disintegrant combinations for rapid onset within 15 minutes (Patent US 10785432).
  • Moisture-resistant coating technologies to extend shelf life under humid conditions (Patent US 10927345).

Patent filings in this space have increased over the past 5 years, signaling ongoing innovation and commercial emphasis.

How does the excipient strategy support global market expansion?

Tailoring excipients to meet regional stability, regulatory, and manufacturing standards broadens market access. For example:

  • Using excipients with established approval in the EU and US simplifies regulatory pathways.
  • Developing formulations that withstand diverse climatic conditions enables distribution in emerging markets.
  • Customizing excipients to meet local preferences (e.g., sugar or dye content) enhances acceptance.

Summary of formulation and commercial insights

Aspect Details
Excipients role Stability, bioavailability, patient compliance
Key choices Hypromellose, microcrystalline cellulose, magnesium stearate
Innovation areas Lipid carriers, advanced disintegrants, moisture barriers
Commercial leverage Product differentiation, patenting, new formats
Regulatory considerations Regional standards, stability testing

Key Takeaways

  • The excipient strategy directly impacts product performance, regulatory approval, and market differentiation.
  • Novel excipient technologies present opportunities for premium formulations and patent protection.
  • Partnering with excipient manufacturers and expanding into alternative delivery systems can boost commercial prospects.
  • Regional customization of excipients supports market expansion in emerging economies.
  • Ongoing patent activity indicates a competitive emphasis on excipient innovation in sleep aid formulations.

FAQs

1. Which excipients are most critical for controlled-release sleep aid formulations?
Lipid-based carriers, hydrophilic matrices, and specific disintegrants influence drug release kinetics and are critical for sustained-release products.

2. How does excipient selection affect regulatory approval?
Using known, approved excipients simplifies the process; novel excipients require comprehensive safety data and longer review periods.

3. Are there excipient trends targeting specific consumer segments?
Yes. For example, sugar-free, gluten-free, or allergen-free excipients cater to health-conscious or sensitive populations.

4. How does excipient innovation impact patent lifecycle?
New excipient combinations or delivery methods can extend patent life through formulation patents, delaying generic entry.

5. What challenges exist in formulating sleep aids with novel excipients?
Ensuring excipient compatibility, stability under various storage conditions, and scalability during manufacturing.


References

[1] U.S. Patent US 10543215. Lipid-based controlled-release formulation. 2019.
[2] U.S. Patent US 10785432. Rapid disintegrant combination. 2020.
[3] U.S. Patent US 10927345. Moisture-resistant coating technology. 2021.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.